Stockscreener 앱 받기
0.975
0.67%
0.0065
전일 마감가:
$0.9685
열려 있는:
$0.97
하루 거래량:
129.35K
Relative Volume:
0.89
시가총액:
$98.21M
수익:
$68.15M
순이익/손실:
$-67.60M
주가수익비율:
-1.4477
EPS:
-0.6735
순현금흐름:
$-41.80M
1주 성능:
-11.76%
1개월 성능:
-37.50%
6개월 성능:
-75.50%
1년 성능:
-72.84%
1일 변동 폭
$0.9177
$1.0099
1주일 범위
$0.8808
$1.08
52주 변동 폭
$0.8808
$5.45
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
0.975 | 98.21M | 68.15M | -67.60M | -41.80M | -0.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-16 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2026-09-15 | 다운그레이드 | Citizens | Mkt Outperform → Mkt Perform |
| 2026-05-28 | 개시 | Barclays | Overweight |
| 2026-02-17 | 재개 | Jefferies | Buy |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2022-05-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Robert W. Baird | Outperform |
| 2020-03-06 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-10-30 | 재개 | Guggenheim | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-05-24 | 재개 | Citigroup | Neutral |
| 2019-03-14 | 개시 | William Blair | Outperform |
| 2018-12-19 | 개시 | Goldman | Neutral |
| 2018-07-16 | 개시 | Barclays | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2017-09-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2017-09-05 | 재확인 | Wells Fargo | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-02-28 | 개시 | Wells Fargo | Outperform |
| 2016-04-05 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | 개시 | BofA/Merrill | Buy |
| 2015-04-20 | 개시 | Jefferies | Buy |
| 2015-04-20 | 개시 | Piper Jaffray | Overweight |
모두보기
Cellectis Adr 주식(CLLS)의 최신 뉴스
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewswire Inc.
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A.CLLS - PR Newswire
CLLS Q2 2026 Earnings: Narrower-Than-Expected Loss as Shares Edge LowerOne-Time Gain Impact - https://www.dars.gov.et/
DBV Technologies S.A. (DBV.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A.CLLS - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS - FinancialContent
Cellectis (CLLS) Down -4.73%: Where Will the Bottom Form? 2026-09-29Undervalued Stocks - siam.in
Cellectis (CLLS) Down -4.73%: Where Will the Bottom Form? 2026-09-29Order Block - https://www.dars.gov.et/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A.CLLS - PR Newswire
Cellectis S.A. (CLLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cellectis S.A.(ENXTPA: ALCLS) added to S&P Global BMI Index - marketscreener.com
Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company - marketscreener.com
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company - marketscreener.com
Cellectis organise une conférence téléphonique et un webcast le 14 septembre pour présenter un point d’activité - GlobeNewswire Inc.
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals - GlobeNewswire Inc.
Cellectis (NASDAQ:CLLS): Is Its Latest Rally More Than Technical? - Kalkine Media
European ADRs Edged Higher As Biotech Led The Pack - Finimize
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionHedge Fund Favorites - siam.in
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionUnusual Call Volume - dars.gov.et
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionFactor Rotation - careplusvn.com
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionHull Moving Average - dars.gov.et
Cellectis (CLLS) Earnings Comparison: EPS Exceeds Its Estimate in the Latest Reading; Reported Share Move - careplusvn.com
CLLS Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.22 Surpasses Estimates; Shares Rise 1.97%Earnings Outlook Update - careplusvn.com
Cellectis (CLLS) Earnings Comparison: EPS Exceeds Its Estimate in the Latest Reading; Reported Share Move - www.dars.gov.et
Cellectis (CLLS) Surges 7.25% to $3.18 as Bullish Momentum BuildsIV Spike - dars.gov.et
Cellectis (CLLS) Surges 7.25% to $3.18 as Bullish Momentum BuildsRetail Driven Moves - careplusvn.com
Cellectis (CLLS) Surges 7.25% to $3.18 as Bullish Momentum BuildsNarrow Range Breakout - siam.in
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Geographic Revenue Trends - careplusvn.com
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Quarterly Profit Report - dars.gov.et
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Guidance vs Actual - www.dars.gov.et
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Consensus Miss Rate - dars.gov.et
Cellectis earnings beat by $0.04, revenue fell short of estimates - Investing.com
Cellectis Reports Financial Results for the Second Quarter 2026 - Barchart.com
Cellectis (CLLS) Slips 1.79% to $2.75 as Gene-Editing Stock Tests Key Technical LevelsLiquidity Sweep - careplusvn.com
Cellectis S.A. Sponsored ADR Revenue Breakdown – LS:A14QZE - TradingView
European ADRs Traded Higher In US Morning Session - Finimize
CLLS Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline, but Shares Edge LowerEarnings Season Review - careplusvn.com
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
European ADRs Jumped As Biotech Led The Pack - Finimize
Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A14QZE Forecast — Price Target — Prediction for 2027 - TradingView
Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS) - TradingView
European ADRs Slip, Even As Biotech Names Edge Higher - Finimize
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - Barchart.com
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewswire Inc.
Cellectis Adr (CLLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
3.98%
자본화:
|
볼륨(24시간):